Pharmaceutical composition comprising nucleic acid with specific sequence, useful for inhibiting expression or activity of tumor-associated antigen, where the tumor associated antigen has a fully defined nucleic acid sequence. The nucleic acid is alternatively one which, under stringent conditions hybridizes, is degenerated with respect to, or is complementary to the foregoing. Pharmaceutical composition comprising nucleic acid with specific sequence, useful for inhibiting expression or activity of tumor-associated antigen, where the tumor associated antigen has a nucleic acid-coded sequence selected from the group comprising sequence identification numbers 1-8, 41-44, 51-59, 84, 117, 119 and 138, a part or derivative of them. The nucleic acid is alternatively one which, under stringent conditions hybridizes, is degenerated with respect to, or is complementary to the foregoing. The composition or agent so determined, is selective for cells which exhibit expression or abnormal expression of a tumor-associated antigen. The agent induces cell death, reduction of cell growth, damage to the cell membrane or secretion of cytokines. Numerous developments and variations in accordance with the foregoing principles are elaborated. Independent claims are included for the following: (1) a method of disease diagnosis； (2) a kit for the purpose of disease diagnosis； (3) a nucleic acid or associated recombinant DNA or RNA molecule； (4) a host cell； (5) a protein, polypeptide； and (6) an immunogenic fragment, antibody or conjugate. ACTIVITY : Cytostatic. MECHANISM OF ACTION : Tumor associated antigen inhibitor.
